Share
PrintBradley Ozenberger, Ph.D.
Extramural Programs Branch
Program Director, Technology Development
Division of Genomic Medicine
Ph.D. University of Missouri, 1988
(301) 496-7531
(301) 480-2770
Room 4076, MSC 9305
Rockville, MD 20892-9305
Dr. Brad Ozenberger administrates The Cancer Genome Atlas (TCGA) program, a large joint effort of the National Human Genome Research Institute (NHGRI) and the National Cancer Institute to generate comprehensive catalogs of genetic aberrations underlying cancer. This ambitious program is analyzing hundreds of cancer specimens each month, characterizing mRNA/miRNA expression and DNA methylation, in addition to genomic sequencing and conducting broad integrative analyses of the genomic and clinical data sets. In addition to his responsibilities coordinating the daily operations of TCGA, Dr. Ozenberger is a co-director of the Medical Sequencing Program and holds the position of Program Director for Technology Development, overseeing a grant portfolio supporting research on the innovative instrumentation and methods that enable today's advances in genomics. Dr. Ozenberger also is involved in the development of NIH policy relating to protection of research participant privacy and data access. Prior to joining NHGRI in 2003, Dr. Ozenberger was a Senior Investigator and Team Leader at Wyeth Pharmaceuticals in Princeton, NJ.
Last Reviewed: May 24, 2012
